Too Early to Tell If J & J Vaccine is "100 Against Death"

The results from an international phase 3 trial of Johnson & Johnson's single-dose COVID-19 vaccine show it is overall 66% effective in preventing moderate to severe symptoms of COVID-19.

The vaccine was 85% effective in preventing severe COVID-19 disease and 100% effective in preventing COVID-19-related hospitalizations and deaths.

According to Forbes, Johnson & Johnson's COVID-19 vaccine hasn't been approved by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA).

FDA officials will then review the submitted data, compile a report, and submit the report to an independent vaccine advisory committee on February 26.

Important to note: the agency needs to thoroughly review the clinical trial data before deciding on an emergency authorization in the middle of a pandemic.

— Ariel Cohen (@ArielCohen37) February 5, 2021

 The Eye Witness News linked J&J Ensemble as the source of information linked in the infographic. Our team didn't find the information mentioned in J&J Ensemble Studies.

The University of Minnesota corrected the headline and text of a story the shared the same claim.

While Johnson and Johnson's widespread, multi-continent study showed it to be 100% effective against death, the vaccine hasn't been approved. The approval process has yet to scrutinize this data. Thus, we have found that it is too early to confirm that the J&J vaccine will be 100% against death once released.